

Monty Montoya Appointed CEO of TherOptix

July 20, 2021 – Boston – Monty Montoya has been named chief executive officer of TherOptix, a pre-clinical biopharma company focused on delivering clinically impactful therapeutics via a drug-eluting contact lens platform. TherOptix has received orphan drug designation on its lead candidate (001) for prevention of proliferative vitreoretinopathy (PVR).

“TherOptix is developing a novel ophthalmic drug delivery platform that has the potential to be a patient game-changer. I look forward to leading this great team through regulatory approval and commercialization,” said Monty Montoya, “TherOptix will offer patients the safest and most efficacious way for critical medicines to be delivered to the front and back of the eye.”

Monty has 30 years of experience in ophthalmology and most recently served as a founder and CEO of CorneaGen and founder of Aurion Biotech. Prior to CorneaGen, Monty served as CEO of SightLife, a global leader in cornea transplant.

“Having watched Monty grow mission-focused companies in multiple settings, I am elated to see him leading TherOptix and look forward to partnering with him and the rest of the team to see patients benefiting from this much-needed drug delivery system,” said Dick Lindstrom, MD, TherOptix board member and ophthalmology icon.

About TherOptix

TherOptix is an early-stage biopharmaceutical company focused on optimizing therapeutic benefit and clinical outcomes by delivering controlled, modifiable drug concentrations through contact lenses to the front and/or back of the eye. The company was founded out of a partnership with Mass Eye & Ear, M.I.T., and Boston Children’s Hospital. The innovative, non-invasive technology platform enables clinically impactful therapeutic delivery.

Media Contact:

Monty Montoya
206-484-0194
Monty@theroptix.com